Authors
Latest:
Subhash Tripathi, PhD, on Generating In Vivo CARs With A2-CAR-CISC EngTreg CellsThe senior researcher at Seattle Children’s discussed the development and validation of A2-CAR-CISC EngTreg cells.
Latest:
Weijia Fang, MD, and Guoqiang Ai, MD, on the Future of IMC001 in Gastric and Colorectal CancerFang commented on a limitation of the clinical trial pointed out at the European Society for Medical Oncology (ESMO) 2022 Congress.
Latest:
Improving Rare Disease Awareness: Bruce Dezube, MDThe senior vice president and head of clinical development at Mustang Bio discussed the importance of Rare Disease Day.
Latest:
CAR T Therapy as a New Option in Non-Hodgkin Lymphoma: Michael R. Bishop, MDThe hematological oncologist from University of Chicago Medicine discussed chimeric antigen receptor T cells therapy in non-Hodgkin lymphoma.
Latest:
George Tachas, PhD, on Tackling DMD Treatment From Multiple AnglesThe lead scientist at Percheron Therapeutics discussed research on antisense oligonucleotide therapies in mouse models of DMD.
Latest:
Tim Miller, PhD, on Supporting Gene Therapy DevelopmentThe cofounder, president, and chief executive officer of Forge Biologics discussed the company’s approach to gene therapy manufacturing.
Latest:
The Future of Gene Therapies in Inherited Retinal DiseasesMariya Moosajee, MBBS, BSc, PhD, FRCOphth, discussed the next generation of gene therapy for inherited retinal diseases.
Latest:
Advantages of Invariant Natural Killer T Cell TherapiesJennifer Buell, PhD, president and chief executive officer, MiNK Therapeutics, discussed the company’s iNKT cell platform.
Latest:
The Power and Potential of Natural Killer Cell Therapies: A New AwakeningNatural killer cells could redefine medicine and offer new hope for cancer, autoimmune diseases, and neurological disorders through advanced CAR-NK therapies.
Latest:
John Leonard, PhD, on RNA-Targeting Gene Therapy for ALS, DMDThe chief scientific officer of LocanaBio discussed preclinical research presented at ASGCT 2023.
Latest:
Commercial Bottlenecks in Gene Therapy DevelopmentNathan Yozwiak, PhD, the head of research at the Gene and Cell Therapy Institute at Mass General Brigham, discussed how innovative research can be held back by financial considerations.
Latest:
Thomas Crawford, MD, on Helping Patients With SMA Left Behind by Gene TherapyThe codirector of the MDA Clinic and professor of neurology at Johns Hopkins discussed the importance of continuing to fight for progress with older patients with SMA.
Latest:
David Boyer, MD, on Promising Efficacy of Suprachoroidal Gene Therapy in nAMDThe senior partner at Retina Vitreous Associates Medical Group discussed efficacy and safety data from the phase 2 AAVIATE trial.
Latest:
Electrotransfection: A Different Approach to Plasmid DeliveryThe chief scientific officer and chief medical officer at Eyevensys discuss the biotech company's pipeline and approach to gene therapy.
Latest:
Daniel Judge, MD, on Translational Gene Therapy for Cardiac DisordersGenetics is the future of heart failure and cardiomyopathy treatment, Judge told CGTLive in an interview.
Latest:
Serena De Vita, MD, PhD, on Speedy Manufacturing of PHE885 for Multiple MyelomaThe senior director and clinical program leader, Translational Clinical Oncology at Novartis Institutes for BioMedical Research, discussed new data from the phase 1 study.
Latest:
Paula Cannon, PhD, on What Attendees Can Look Forward to at ASGCT’s 2024 MeetingThe President Elect of ASGCT and a distinguished professor of microbiology at Keck School of Medicine of USC also discussed recent milestones in gene therapy.
Latest:
Ula V. Jurkunas, MD: CALEC Transplant Feasible for Limbal Stem Cell DeficiencyThe associate professor of ophthalmology at Harvard Medical School discussed early results from a phase 1/2 trial from Mass Eye and Ear and partners.
Latest:
Raphaël Ognar on Adding New Options to the Oncologic Cell Therapy ArsenalThe cofounder and chief executive officer of NKILT Therapeutics discussed unique advantages of the CIR platform.
Latest:
Bone Marrow DNA Sequencing Predicts Acute Lymphoblastic Leukemia Relapse After TisagenlecleucelFindings from the phase 2 ENSIGN and ELIANA studies suggest DNA sequencing predicts ALL relapse.
Latest:
Diane Simeone, MD, on Screening Patients for CAR-T Eligibility Before Solid Tumor RelapseSimeone discussed the progress and challenges seen so far in the BASECAMP-1 observational study.
Latest:
Francesca Del Bufalo, MD, PhD, on Evaluating GD2-Directed CAR-T in Pediatric NeuroblastomaThe medical doctor and scientist at Bambino Gesù Chidren’s Hospital discussed phase 1/2 clinical trial data she presented at ASGCT’s 2024 Meeting.
Latest:
Florian Eichler, MD, on Addressing Unmet Needs in Canavan Disease With Gene TherapyThe neurologist at Massachusetts General Hospital discussed BBP-812, an investigational AAV vector-based gene therapy being evaluated for Canavan disease in a phase 1/2 trial.
Latest:
Cell Therapy May Yield Deep Remissions in Multiple MyelomaIde-cel's March 2021 FDA approval marks a significant advance in relapsed/refractory multiple myeloma treatment.
Latest:
Bruce Cree, MD, PhD, MAS, on the Importance of Understanding Disease Pathobiology for Novel Treatment ApproachesThe clinical research director of the UCSF Multiple Sclerosis Center discussed the difference between developing targeted therapies for well-understood diseases like SCD and less well-understood diseases like MS.
Latest:
Raising Awareness of CAR T Therapy for Mantle Cell Lymphoma: Luhua Wang, MDThe professor from The University of Texas MD Anderson Cancer Center discussed growing awareness of CAR T-cell therapy among community oncologists and patients with mantle cell lymphoma.
Latest:
Diana Bharucha-Goebel, MD, and Bakri Elsheikh, MBBS, FRCP, on Setting Realistic Goals for Long-Standing SMAThe clinical neurophysiologist at Children’s National and the professor of neurology at The Ohio State University Wexner Medical Center discussed treatment considerations for patients already living with SMA.
Latest:
Shankar Musunuri, PhD, on Continuing Research With Gene Therapy in Inherited Retinal DiseasesThe chairman, chief executive officer, and cofounder of Ocugen discussed programs including OCU400 and OCU410.
Latest:
Peter Bross, MD, on the Importance of Transparency and Communication With the FDAThe chief of the oncology branch of the Center for Biologics Evaluation and Research at the FDA discussed how academia and industry can work best with regulatory agencies.
